WASHINGTON --
The U. S. Food and Drug Administration today approved an Abbreviated New Drug Application (ANDA) for the oral reuptake inhibitor Zepbound, approved on July 18, 2007.
The ANDA is an amendment to the FDA's Abbreviated New Drug Application (ANDA), which is a prescription drug application (a "PDA") that requires a patient to complete a detailed written list of all known and potential drug interactions.
In addition, the ANDA is an amendment to the Food and Drug Administration's Drug Safety Information (DSI) for the drug's "bioequivalence" to other approved drugs, as defined in the USFDA's Guidance on Drug Safety for Drugs
for the following drugs:
Zepbound (bupropion) (Liraglutide, Zyprexa, Zydis) (citalopram, fluoxetine) (Prochlorper, Prozac, Fexoquel, Fosphenytoin, Zyprexa, Zyprexa XL, Zyprexa SR)
Zepbound (bupropion) is aripiprazole (Zyprexa SR)
Zepbound is aripiprazole (Zydis) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is an atazanavir is aripiprazole is aripiprazole (Aripiprazole)
Zepbound (bupropion) is aripiprazole (Zydis) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR)
Zepbound (bupropion) is aripiprazole (Zydis) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis SR)
Zepbound (bupropion) is aripiprazole (Zydis) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR)
In short, the ANDA is an amendment to the FDA's Drug Safety Information (DSI) for the drug's "bioequivalence to other approved drugs" as defined in the USFDA's Guidance on Drug Safety for Drugs
Zepbound (bupropion) (Liraglutide, Zyprexa, Zydis) (citalopram, fluoxetine) (Prochlorper, Prozac, Fexoquel, Fosphenytoin, Zyprexa, Zyprexa XL, Zyprexa SR) is aripiprazole (Zydis), aripiprazole (Zydis XL) is aripiprazole (Zydis SR).
Zepbound (bupropion) is aripiprazole (Zydis) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR) is aripiprazole (Zydis XL).
Zepbound (bupropion) is aripiprazole (Zydis) is aripiprazole (Zydis XL) is aripiprazole (Zydis SR).
The National Institute on Aging and other federal agencies are investigating a new antipsychotic drug, Zyprexa, to treat bipolar disorder.
The new antipsychotic drug, Zyprexa, will be available by prescription only from the Food and Drug Administration (FDA), as well as through pharmacies.
The agency will also investigate whether the new drug has caused a “black box warning” or other adverse side effects, the agency said.
In an email, Eli Lilly released a statement saying the drug has been discontinued.
The agency also said the new drug is being developed to treat bipolar disorder by other medications, including another antipsychotic, olanzapine.
The drug is not approved for use in the United States, though it was approved to treat a wide range of conditions including schizophrenia and bipolar disorder.
The drug was launched in the United States in 1997. A generic version of Zyprexa was approved in 2007.
The drug is also approved to treat schizophrenia and bipolar disorder in children and adolescents with bipolar disorder, and in adults, according to the agency.
In a statement, Eli Lilly said: "In this new effort to treat bipolar disorder, the Food and Drug Administration is conducting a study to determine the safety and efficacy of the new drug for the treatment of bipolar disorder in individuals with bipolar disorder, a condition in which the brain's ability to sense and/or respond to mood-related stimuli is compromised. This study is expected to be completed in the near future.
"While the drug is being studied, we believe it is the first antipsychotic medication approved for this indication. It is not approved for use in the United States."
The agency said the new drug is not designed to treat patients with schizophrenia or bipolar disorder, but to treat patients with the condition by altering their mood.
The FDA will also examine the safety and efficacy of the drug, the agency said.
The agency also said it plans to continue the work on other antipsychotic drugs to assess whether the new drug is safe and effective.
The agency also announced it was working on a new drug that will help patients who need to take the drug in addition to the usual dosage of the medication. However, the agency is also reviewing a new treatment for people with bipolar disorder.
The agency also said it plans to continue reviewing its studies of the new antipsychotic drug, including the use of olanzapine, in treating patients with bipolar disorder.
The agency also announced it was working on a new drug that could be used to treat people with schizophrenia.
The agency said it has not received reports of a patient developing side effects from the drug, and that the new drug is not being studied for these reasons.
A total of 5,822 patients with schizophrenia and 5,988 patients with bipolar disorder were prescribed Zyprexa as part of the study, according to the agency.
The agency said it will continue the work on a new drug that may be used to treat patients with bipolar disorder.
The agency also announced it is working on a new drug that can be used to treat people with schizophrenia.
The agency also said it is working to examine the safety and efficacy of the drug, the agency said.
The drug is approved by the FDA for the treatment of schizophrenia and bipolar disorder in adults, but it is not approved for use in children and adolescents with bipolar disorder.
The agency said that the new drug is not intended to treat any conditions that are listed in a warning for schizophrenia.
The agency also said it is working on a new drug that could be used to treat people with bipolar disorder.
The agency also said it is working to investigate the risks and benefits of the drug, the agency said.
The agency also announced that the agency will be conducting an additional clinical trial to determine whether patients taking the drug for schizophrenia or bipolar disorder can be safely treated with the new drug.
The agency said the trial will be ongoing, and will continue to evaluate the drug as a treatment for schizophrenia and bipolar disorder.
The drug has not been approved for use in the United States, but it has been approved to treat a wide range of conditions in which the brain’s ability to sense and/or respond to mood-related stimuli is compromised. This includes schizophrenia, bipolar disorder and other psychiatric disorders.
Zyprexa (Zyprexa XR) is an oral, weight-loss medication that is used primarily to manage schizophrenia, bipolar disorder, and mixed episodes of bipolar disorder. Zyprexa works by affecting the neurotransmitter activity in the brain. It is believed to work by affecting the reuptake of presynaptic dopamine, a neurotransmitter that plays a key role in regulating mood, emotions, and other physiological functions. Zyprexa XR may also be used for purposes not listed in this medication guide.
Zyprexa (Zyprexa XR) is a medication that belongs to a class of drugs known as atypical antipsychotics. It works by affecting the neurotransmitter activity in the brain, which is thought to play a role in mood regulation and decision-making. Zyprexa XR is primarily used to manage schizophrenia and bipolar disorder. It can also be used for other conditions such as:
Zyprexa (Zyprexa XR) has been approved by the U. S. Food and Drug Administration (FDA) for use in adults and pediatric patients aged 4 years and older. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Zyprexa (Zyprexa XR) has been approved for use in a number of different populations, including adults and children. For some populations, the medication may not be appropriate for children or adolescents below the age of 4 years old.
The U. S. Food and Drug Administration is warning consumers not to use an antipsychotic drug called Zyprexa because of serious side effects, including an increased risk of dementia. The FDA issued a warning letter in June 2010, saying the drug, which is sold under the brand name Zyprexa, can cause serious changes in the brain. In a separate announcement Thursday, the FDA said it is taking steps to address the side effects.
The announcement came a month after an advisory panel concluded that an antipsychotic, which has been called the "first-line antipsychotic," carries a risk of serious side effects. The FDA said it is taking additional steps to ensure people are not taking an antipsychotic.
In a letter issued on Thursday, the FDA said it has taken steps to address the side effects associated with Zyprexa and the risk of dementia. It did not say whether the risk was increased by weight loss or other risks.
"We are taking steps to ensure that the labeling of any new drug or treatment is accurate and complete and that the label insert is carefully followed," the FDA said in a statement. "This letter is the latest attempt by the FDA to inform the public about the safety and efficacy of Zyprexa. We expect that public awareness initiatives will be an integral part of the FDA's efforts to address this important health concern."
The warning letter is part of the FDA's effort to ensure the safety and efficacy of antipsychotic medications, including Zyprexa, to people who have serious or persistent side effects. Zyprexa is also being marketed as a treatment for schizophrenia.
In June 2010, a federal judge ruled in favour of the drug maker's motion to dismiss the suit. The company appealed the ruling.
The FDA's warning letter says Zyprexa can cause changes in the brain, including increased activity in the hypothalamus and decreased activity in the area of the brain known as the nucleus accumbens, which is responsible for controlling dopamine.
The agency also says that the company has not been found to have a significant risk of dementia or other serious medical problems. The warning letter also says Zyprexa is linked to a "very rare but very serious" potential drug reaction called neuroleptic malignant syndrome.
In a statement to the FDA, the company said, "The FDA continues to monitor patients and is working to ensure that any new adverse events are reported to the agency and the patient is provided with proper medical care and guidance."
The FDA is also investigating whether Zyprexa could have dangerous interactions with other medicines and other drugs, including blood thinners, antipsychotics and steroids.
The company is not releasing details about its product information.
Copyright © 2025 WL-FDA. All rights reserved.
Read on to learn more about the FDA's new drug warnings, latest safety information, new directions for use and more.Last updated: 2025-02-08
For more information about the FDA's safety alerts, please see the
Read more about:For more information about the FDA's new drug warnings, please see the
Last reviewed: June 25, 2025Consumer Affairshas received the following reports of serious side effects or adverse events from this product:
Consumer Affairs is voluntarily recalling a total of 250 mg of Olanzapine from its U. distribution program because of a reported increased risk of heart attack and stroke in some patients. This is the second recall of the medicine. The recall was in response to a recent study of Olanzapine and other similar antipsychotic medications in patients with schizophrenia. The product was recalled in Canada on March 7, 2025 due to an increased risk of heart attack and stroke. The product is being distributed to approximately 100 patients in the U. and Canada.
Consumer Alertsis arranging for a response from the manufacturer, Bayer AG, the U.
Stade de France Pharmacy